P3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial)

View/ Open
Date
2017-01ICR Author
Author
Popat, S
Hughes, L
O'Brien, M
Ahmad, T
Lewanski, C
Dernedde, U
Jankowska, P
Mulatero, C
Shah, R
Hicks, J
Geldart, T
Cominos, M
Gray, G
Spicer, J
Bell, K
Ngai, Y
Hackshaw, A
Type
Journal Article
Metadata
Show full item recordCollections
Language
eng
License start date
2017-01
Citation
Journal of Thoracic Oncology, 2017, 12 (1), pp. S1215 - S1216
Publisher
Elsevier BV